Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

exenatide

subcutaneous injection, 2.0mcg, once weekly

Trial Locations (26)

Unknown

Research Site, Mesa

Research Site, Tempe

Research Site, Concord

Research Site, Fresno

Research Site, La Mesa

Research Site, Atlanta

Research Site, Idaho Falls

Research Site, Bowling Green

Research Site, Corvallis

Research Site, Chattanooga

Research Site, Memphis

Research Site, New Westminster

Research Site, Ajax

Research Site, Cambridge

Research Site, Windsor

Research Site, Chihuahua City

Research Site, Monterrey

Research Site, Distrito Federal

Research Site, Baia Mare

Research Site, Brasov

Research Site, Bucharesti

Research Site, Craiova

Research Site, Iași

Research Site, Suceava

Research Site, Johannesburg

Research Site, Pretoria

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY